Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence
Provided herein are isolated polynucleotide encoding modified click beetle luciferase polypeptides that have enhanced luminescence and longer wavelength near-infrared signals. The disclosure also relates to near-infrared bioluminescence systems that include said modified click beetle luciferase polypeptides and novel luciferin derivatives, as well as methods of using said modified click beetle luciferase polypeptides and bioluminescence systems.
1. An isolated polynucleotide encoding a click beetle red luciferase (CBR) variant polypeptide having at least 80% amino acid sequence identity to SEQ ID NO: 1 and comprising at least one amino acid substitution at position 4, 51, 52, 72, 109, 119, 156, 226, 229, 251, 281, 334, 337, 350, 389, 393, 409, 422, 439, 444, 445, 479, 489, 503, 508, 531, 535, or 537, or a combination thereof, corresponding to SEQ ID NO: 1;
wherein the amino acid substitution at position 337 is F337E, the amino acid substitution at position 389 is I389F, the amino acid substitution at position 444 is S444R, and the amino acid substitution at position 109 is I109N; and
wherein the variant CBR polypeptide has at least one of enhanced luminescence, altered light emission wavelength, altered substrate specificity, or a combination thereof, as compared to a CBR polypeptide of SEQ ID NO: 1.
2. The isolated polynucleotide of claim 1 , wherein the CBR variant polypeptide comprises at least one amino acid substitution at position 51, 251, 334, 389, or 444, or a combination thereof, corresponding to SEQ ID NO: 1.
3. The isolated polynucleotide of claim 2 , wherein the CBR variant polypeptide comprises at least one of the following amino acid substitutions corresponding to SEQ ID NO: 1: S51N, G251S, or R334S.
4. The isolated polynucleotide of claim 1 , wherein the CBR variant polypeptide comprises at least one amino acid substitution at position 4, 52, 72, 109, 119, 156, 226, 229, 281, 337, 350, 393, 409, 422, 439, 445, 479, 489, 503, 508, 531, 535, or 537, or a combination thereof, corresponding to SEQ ID NO: 1.
5. The isolated polynucleotide of claim 4 , wherein the CBR variant polypeptide comprises at least one of the following amino acid substitutions corresponding to SEQ ID NO: 1: R4H, Y52C, K72E, I109N, I119F, N156K, T226H, T226G, T226C, T226Y, T226N, T226Q, I229V, S281N, S281Q, K337E, L350P, M393L, I409T, Y422C, I439V, Q445H, S479T, E489V, V503M, Y508C, E531G, Q535H, or L537W.
6. The isolated polynucleotide of claim 1 , wherein the sequence has been codon-optimized.
7. The isolated polynucleotide of claim 1 , wherein the polynucleotide further encodes a polypeptide of interest linked to the CBR variant polypeptide, the polypeptide of interest and the CBR variant polypeptide capable of being expressed as a fusion protein.
8. The isolated polynucleotide of claim 1 , wherein the CBR variant polypeptide comprises amino acid substitutions at the following positions corresponding to SEQ ID NO: 1:
(i) 4 and 229 of SEQ ID NO: 1;
(ii) 350 and 535 of SEQ ID NO: 1;
(iii) 156 and 445 of SEQ ID NO: 1; or
(iv) 422 and 531 of SEQ ID NO: 1.
9. The isolated polynucleotide of claim 8 , wherein the CBR variant polypeptide comprises the amino acid substitutions at the following positions corresponding to SEQ ID NO: 1:
(i) R4H and I229V;
(ii) L350P and Q535H;
(iii) N156K and Q445H; or
(iv) Y422C and E531G.
10. A vector comprising the polynucleotide, or a fragment thereof, of claim 1 .
11. The vector of claim 10 , wherein the polynucleotide is operably linked to a promoter.
12. A cell comprising the polynucleotide of claim 1 .
13. A CBR variant polypeptide encoded by the polynucleotide of claim 1 .
14. A circularly permuted luciferase comprising the polypeptide encoded by the polynucleotide of claim 1 or a fragment thereof.
15. A fusion protein comprising a CBR variant polypeptide encoded by the polynucleotide of claim 1 .
16. A near-infrared bioluminescence system comprising the polynucleotide of claim 1 and a luciferin derivative.
17. A kit comprising the polynucleotide of claim 1 .
18. The kit of claim 17 , further comprising at least one of:
(a)
and
(b) a buffer reagent.